The Medicines CompanyMDCO announced that it has completed patient enrollment ahead of schedule in the phase III TANGO 1 study on one of its pipeline candidates, Carbavance (meropenem-vaborbactam), for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results